Cefaclor

CAS No:
53994-73-3 Categories: , ,
  • #LGM Pharma is a Cefaclor CAS# 53994-73-3 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 53994-73-3
  • AHFC code: 08:12.06.08
  • Synonyms: CCL Cefaclor anhydrous Cefaclorum [INN-Latin] Cephaclor
  • ATC Code: J01DC04
  • Chemical Formula: C16H26N2O5S
  • Molecular Weight: 367.807
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00833 (APRD00243)
  • SMILES: [H][C,]12SCC(Cl)=C(N1C(=O)[C,H]2NC(=O)[C,H](N)C1=CC=CC=C1)C(O)=O
  • InChl: QYIYFLOTGYLRGG-GPCCPHFNSA-N
  • PubChem: 51038
  • IUPAC: (6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Additional Details

Indication:
For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Pharmacodynamics:
Cefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes – Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A _-hemolytic streptococci). Gram-negative aerobes – Escherichia coli, Haemophilus influenzae (including _-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.
Mode of Action:
Cefaclor, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that cefaclor interferes with an autolysin inhibitor.
Metabolism:
No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).
Toxicity:
Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
General Reference:
Hebert AA, Sigman ES, Levy ML: Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991 Nov;25(5 Pt 1):805-8. Pubmed Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T: Serum sickness-like syndrome associated with cefaclor therapy. Allergy. 1992 Aug;47(4 Pt 2):439-40. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos